Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
McKesson
Dow
AstraZeneca

Last Updated: November 21, 2019

23 Drugs Facing Patent Expirations and Generic Entry in 2019 - 2020

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "23 Drugs Facing Patent Expirations and Generic Entry in 2019 - 2020" DrugPatentWatch.com thinkBiotech, 2019 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIMBRINZA (brimonidine tartrate; brinzolamide) generic drug versions launch?

Generic name: brimonidine tartrate; brinzolamide
Patent Expiration / Generic Entry Opportunity December 07, 2019
Generic Entry Controlled by: Patent 6,316,441

Drug Price Trends for SIMBRINZA
SIMBRINZA is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has forty-one patent family members in twenty-five countries.

See drug price trends for SIMBRINZA.

The generic ingredient in SIMBRINZA is brimonidine tartrate; brinzolamide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the brimonidine tartrate; brinzolamide profile page.

When can DUREZOL (difluprednate) generic drug versions launch?

Generic name: difluprednate
Patent Expiration / Generic Entry Opportunity December 13, 2019
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for DUREZOL
DUREZOL is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in five countries. There has been litigation on patents covering DUREZOL

See drug price trends for DUREZOL.

The generic ingredient in DUREZOL is difluprednate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the difluprednate profile page.

When can VASCEPA (icosapent ethyl) generic drug versions launch?

Generic name: icosapent ethyl
Patent Expiration / Generic Entry Opportunity January 27, 2020
Generic Entry Controlled by: Patent 8,188,146

Drug Price Trends for VASCEPA
VASCEPA is a drug marketed by Amarin Pharms. There are twenty-five patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and thirty-three patent family members in forty-one countries. There has been litigation on patents covering VASCEPA

See drug price trends for VASCEPA.

The generic ingredient in VASCEPA is icosapent ethyl. There are twelve drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the icosapent ethyl profile page.

When can POMALYST (pomalidomide) generic drug versions launch?

Generic name: pomalidomide
Patent Expiration / Generic Entry Opportunity February 08, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

POMALYST is a drug marketed by Celgene. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and sixty-three patent family members in forty-six countries. There has been litigation on patents covering POMALYST

See drug price trends for POMALYST.

The generic ingredient in POMALYST is pomalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pomalidomide profile page.

When can JUXTAPID (lomitapide mesylate) generic drug versions launch?

Generic name: lomitapide mesylate
Patent Expiration / Generic Entry Opportunity February 21, 2020
Generic Entry Controlled by: Patent 5,712,279

JUXTAPID is a drug marketed by Aegerion. There are nine patents protecting this drug.

This drug has ninety-one patent family members in thirty-seven countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

When can APTIVUS (tipranavir) generic drug versions launch?

Generic name: tipranavir
Patent Expiration / Generic Entry Opportunity April 29, 2020
Generic Entry Controlled by: Patent 5,852,195

Drug Price Trends for APTIVUS
APTIVUS is a drug marketed by Boehringer Ingelheim. There are three patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-one countries.

See drug price trends for APTIVUS.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tipranavir profile page.

When can ABLAVAR (gadofosveset trisodium) generic drug versions launch?

Generic name: gadofosveset trisodium
Patent Expiration / Generic Entry Opportunity May 04, 2020
Generic Entry Controlled by: Patent 6,676,929

ABLAVAR is a drug marketed by Lantheus Medcl. There is one patent protecting this drug.

This drug has forty-three patent family members in twenty-six countries.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

When can FORTOVASE (saquinavir) generic drug versions launch?

Generic name: saquinavir
Patent Expiration / Generic Entry Opportunity May 16, 2020
Generic Entry Controlled by: Patent 6,352,717

FORTOVASE is a drug marketed by Hoffmann La Roche. There is one patent protecting this drug.

This drug has forty patent family members in thirty-four countries.

The generic ingredient in FORTOVASE is saquinavir. There is one drug master file entry for this API. Additional details are available on the saquinavir profile page.

When can VIVITROL (naltrexone) generic drug versions launch?

Generic name: naltrexone
Patent Expiration / Generic Entry Opportunity May 19, 2020
Generic Entry Controlled by: Patent 6,264,987

Drug Price Trends for VIVITROL
VIVITROL is a drug marketed by Alkermes. There are thirteen patents protecting this drug.

This drug has one hundred and thirteen patent family members in twenty-eight countries. There has been litigation on patents covering VIVITROL

See drug price trends for VIVITROL.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the naltrexone profile page.

When can EGRIFTA (tesamorelin acetate) generic drug versions launch?

Generic name: tesamorelin acetate
Patent Expiration / Generic Entry Opportunity May 26, 2020
Generic Entry Controlled by: Patent 5,861,379

EGRIFTA is a drug marketed by Theratechnologies. There are five patents protecting this drug.

This drug has forty-four patent family members in sixteen countries.

See drug price trends for EGRIFTA.

The generic ingredient in EGRIFTA is tesamorelin acetate. One supplier is listed for this generic product. Additional details are available on the tesamorelin acetate profile page.

When can QSYMIA (phentermine hydrochloride; topiramate) generic drug versions launch?

Generic name: phentermine hydrochloride; topiramate
Patent Expiration / Generic Entry Opportunity June 14, 2020
Generic Entry Controlled by: Patent 7,674,776

Drug Price Trends for QSYMIA
QSYMIA is a drug marketed by Vivus. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-four patent family members in nineteen countries. There has been litigation on patents covering QSYMIA

See drug price trends for QSYMIA.

The generic ingredient in QSYMIA is phentermine hydrochloride; topiramate. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the phentermine hydrochloride; topiramate profile page.

When can DENAVIR (penciclovir) generic drug versions launch?

Generic name: penciclovir
Patent Expiration / Generic Entry Opportunity June 17, 2020
Generic Entry Controlled by: Patent 5,075,445

Drug Price Trends for DENAVIR
DENAVIR is a drug marketed by Mylan. There are two patents protecting this drug.

This drug has one hundred and five patent family members in thirty-four countries. There has been litigation on patents covering DENAVIR

See drug price trends for DENAVIR.

The generic ingredient in DENAVIR is penciclovir. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the penciclovir profile page.

When can VIMOVO (esomeprazole magnesium; naproxen) generic drug versions launch?

Generic name: esomeprazole magnesium; naproxen
Patent Expiration / Generic Entry Opportunity July 06, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

VIMOVO is a drug marketed by Horizon. There are eleven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-one patent family members in twenty-three countries. There has been litigation on patents covering VIMOVO

See drug price trends for VIMOVO.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the esomeprazole magnesium; naproxen profile page.

When can VYXEOS (cytarabine; daunorubicin ) generic drug versions launch?

Generic name: cytarabine; daunorubicin
Patent Expiration / Generic Entry Opportunity August 03, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

VYXEOS is a drug marketed by Celator Pharms. There are eight patents protecting this drug.

This drug has one hundred and thirteen patent family members in twenty-one countries.

See drug price trends for VYXEOS.

The generic ingredient in VYXEOS is cytarabine; daunorubicin . There are fifteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cytarabine; daunorubicin profile page.

When can CIPRODEX (ciprofloxacin; dexamethasone) generic drug versions launch?

Generic name: ciprofloxacin; dexamethasone
Patent Expiration / Generic Entry Opportunity August 10, 2020
Generic Entry Controlled by: Patent 6,284,804

CIPRODEX is a drug marketed by Novartis. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty-two countries. There has been litigation on patents covering CIPRODEX

See drug price trends for CIPRODEX.

The generic ingredient in CIPRODEX is ciprofloxacin; dexamethasone. There are thirty-four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the ciprofloxacin; dexamethasone profile page.

When can DOTAREM (gadoterate meglumine) generic drug versions launch?

Generic name: gadoterate meglumine
Patent Expiration / Generic Entry Opportunity August 25, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

DOTAREM is a drug marketed by Guerbet.

This drug has thirteen patent family members in twelve countries.

See drug price trends for DOTAREM.

The generic ingredient in DOTAREM is gadoterate meglumine. One supplier is listed for this generic product. Additional details are available on the gadoterate meglumine profile page.

When can BIDIL (hydralazine hydrochloride; isosorbide dinitrate) generic drug versions launch?

Generic name: hydralazine hydrochloride; isosorbide dinitrate
Patent Expiration / Generic Entry Opportunity September 08, 2020
Generic Entry Controlled by: Patent 6,465,463

BIDIL is a drug marketed by Arbor Pharms Llc. There are two patents protecting this drug.

This drug has four patent family members in four countries.

See drug price trends for BIDIL.

The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.

When can RAPIVAB (peramivir) generic drug versions launch?

Generic name: peramivir
Patent Expiration / Generic Entry Opportunity September 20, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

RAPIVAB is a drug marketed by Biocryst. There are four patents protecting this drug.

This drug has sixty-three patent family members in twenty-eight countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
Patent Expiration / Generic Entry Opportunity October 15, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries.

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can THALOMID (thalidomide) generic drug versions launch?

Generic name: thalidomide
Patent Expiration / Generic Entry Opportunity October 23, 2020
Generic Entry Controlled by: Patent 8,626,531

THALOMID is a drug marketed by Celgene. There are nine patents protecting this drug and three Paragraph IV challenges.

This drug has forty-seven patent family members in nineteen countries. There has been litigation on patents covering THALOMID

See drug price trends for THALOMID.

The generic ingredient in THALOMID is thalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the thalidomide profile page.

When can ESKATA (hydrogen peroxide) generic drug versions launch?

Generic name: hydrogen peroxide
Patent Expiration / Generic Entry Opportunity December 14, 2020
Generic Entry Controlled by: FDA Regulatory Exclusivity

ESKATA is a drug marketed by Aclaris. There are four patents protecting this drug.

This drug has twenty-six patent family members in fifteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the hydrogen peroxide profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
AstraZeneca
Mallinckrodt
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.